Article

Dorzolomide HCI OK for use in children

The FDA has approved Merck Human Health's dorzolomide HCI (Trusopt) ophthalmic solution 2% for use in pediatric patients. The drug is used to treat elevated IOP in patients with ocular hypertension or open-angle glaucoma.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
Japanese researchers link outdoor time to rapid increase in choroidal thickness
August 9th 2025

Japanese researchers link outdoor time to rapid increase in choroidal thickness

ROP: Treating and preventing blindness in preterm babies
August 9th 2025

ROP: Treating and preventing blindness in preterm babies

Children with ADHD may be less likely to develop myopia, study suggests
August 9th 2025

Children with ADHD may be less likely to develop myopia, study suggests

Managing a changing landscape of IRD pediatric cases
August 9th 2025

Managing a changing landscape of IRD pediatric cases

Study shows ceftriaxone found effective in treating congenital syphilis
August 9th 2025

Study shows ceftriaxone found effective in treating congenital syphilis

European Commission approves low-dose atropine eye drop Ryjunea from Santen
August 9th 2025

European Commission approves low-dose atropine eye drop Ryjunea from Santen

© 2025 MJH Life Sciences

All rights reserved.